Cancer immunotherapy with CpG-ODN;Immunothérapie des cancers par oligonucléotides immunostimulants

Medecine/Sciences

Volumn 21, Issue 1, 2005, Pages 73-77

  Carpentier, Antoine F ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; OLIGODEOXYNUCLEOTIDE; RITUXIMAB; TOLL LIKE RECEPTOR 9; TRASTUZUMAB;

ALLERGY; B LYMPHOCYTE; CPG ISLAND; DENDRITIC CELL; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFECTION; NONHUMAN; PHENOTYPE; REVIEW;

BACTERIA (MICROORGANISMS);

EID: 12344307629     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200521173     Document Type: Review

References (38)

1. Tokunaga T, Yamamoto H, Shimada S, et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 1984; 72: 955-62.
2. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-9.
3. Yamamoto S, Yamamoto T, Kataoka T, et al. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J Immunol 1992; 148: 4072-6.
4. Hacker H. Signal transduction pathways activated by CpG-DNA. Curr Top Microbiol Immunol 2000; 247: 77-92.
5. Hemmi H, Takeuchi O, Kawai T, et al. Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5.
6. Takeshita F, Leifer CA, Gursel I, et al. Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 2001; 167: 3555-8.
7. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004; 4: 249-59.
8. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168: 4531-7.
9. Carpentier AF, Auf G, Delattre JY. CpG-oligonucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma. Front Biosci 2003, 8: E115-27.
10. Jung J, Yi AK, Zhang X, et al. Distinct response of human B cell subpopulations inrecognition of an innate immune signal, CpG DNA. J Immunol 2002; 169: 2368-73.
11. Sparwasser T, Koch ES, Vabulas RM, et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998; 28: 2045-54.
12. Ban E, Dupre L, Hermann E, et al. CpG motifs induce Langerhans cell migration in vivo. Int Immunol 2000; 12: 737-45.
13. Krug A, Towarowski A, Britsch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001; 31: 3026-37.
14. Kline JN, Waldschmidt TJ, Businga TR, et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998; 160: 2555-9.
15. Cho HJ, Takabayashi K, Cheng PM, et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol 2000; 18: 509-14.
16. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 2004; 6: 88-95.
17. Hartmann G, Weeratna RD, Ballas ZK, et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000; 164: 1617-24.
18. Carpentier AF, Chen L, Maltonti F, Delattre JY. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999; 59: 5429-32.
19. Carpentier AF, Xie J, Mokhtari K, Delattre JY. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 2000; 6: 2469-73.
20. Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000; 95: 999-1006.
21. Hafner M, Zawatzky R, Hirtreiter C, et al. Antimetastatic effect of CpG DNA mediated by type I IFN. Cancer Res 2001; 61: 5523-8.
22. Lanuti M, Rudginsky S, Force SD, et al. Cationic lipid/bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Cancer Res 2000; 60: 2955-63.
23. + T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 2001; 167: 5247-53
24. Hartmann E, Wollenberg B, Rothenfusser S, et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 2003; 63: 6478-87.
25. Vicori AP, Chiodoni C, Vaure C, et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002; 196: 541-9.
26. nd International Symposium Activating immunity with CpG Oligos. Amelia Island, Florida, 7-10 octobre 2001.
27. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-60.
28. Zwaveling S, Ferreira Mota SC, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002; 169: 350-8.
29. Miconnet I, Koenig S, Speiser D, et al. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol 2002; 68: 1212-8.
30. Davila E, Celis E. Repeated administration of cytosine-phosphorotholated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol 2000; 165: 539-47.
31. Tighe H, Takabayashi K, Schwartz D, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000; 106: 124-34.
32. Kim SK, Ragupathi G, Cappello S, et al. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUCl-KLH and GD3-KLH conjugates. Vaccine 2000; 19: 530-7.
33. Liu HM, Newbrough SE, Bhatia SK, et al. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood 1998; 92: 3730-6.
34. Warren TL, Dahle CE, GJ Weiner. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. Clin Lymphoma 2000; 1: 57-61.
35. Decker T, Hipp S, Kreitman RJ, et al. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood 2002; 99: 1320-6.
36. Egeter OR, Mocikat K, Ghoreschi A, et al. Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice. Cancer Res 2000; 60: 1515-20.
37. Heckelsmiller K, Beck S, Rall K, et al. Combined dendritic cell and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol 2002; 32: 3235-45.
38. Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 2003; 9: 3105-14.